Holowesko Partners’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-49,000
Closed -$2.85M 30
2020
Q4
$2.85M Hold
49,000
0.77% 22
2020
Q3
$3.1M Hold
49,000
0.52% 18
2020
Q2
$3.77M Sell
49,000
-159,000
-76% -$12.2M 0.45% 20
2020
Q1
$15.6M Sell
208,000
-909,000
-81% -$62.8M 1.7% 16
2019
Q4
$72.6M Hold
1,117,000
4.47% 11
2019
Q3
$70.8M Sell
1,117,000
-20,000
-2% -$1.31M 5.61% 10
2019
Q2
$76.8M Buy
+1,137,000
New +$74.8M 6.33% 8
2018
Q3
Sell
-920,000
Closed -$65.2M 28
2018
Q2
$65.2M Sell
920,000
-30,000
-3% -$2.12M 4.39% 11
2018
Q1
$71.6M Sell
950,000
-268,000
-22% -$21.3M 4.93% 7
2017
Q4
$87.3M Hold
1,218,000
5.51% 7
2017
Q3
$98.7M Buy
1,218,000
+13,000
+1% +$994K 7.86% 5
2017
Q2
$85.3M Hold
1,205,000
5.76% 5
2017
Q1
$81.8M Buy
1,205,000
+155,000
+15% +$10.9M 4.9% 9
2016
Q4
$75.2M Buy
1,050,000
+526,000
+100% +$39.1M 5.25% 5
2016
Q3
$41.5M Buy
524,000
+17,000
+3% +$1.38M 3.71% 15
2016
Q2
$42.3M Hold
507,000
3.56% 15
2016
Q1
$46.6M Buy
507,000
+173,000
+52% +$15.6M 3.38% 15
2015
Q4
$33.8M Buy
334,000
+102,000
+44% +$10.6M 2.2% 20
2015
Q3
$22.8M Buy
+232,000
New +$25.8M 1.59% 25

Other funds holding GILD

Holowesko Partners's GILD Position: Q1 2021 in Review

Holowesko Partners sold out of Gilead Sciences (GILD) in Q1 2021, closing a stake of 49,000 shares — an estimated $2.85M sold.

Holowesko Partners first reported a position in GILD in Q3 2015 and held it in 19 quarters. The position peaked at $98.7M in Q3 2017. 1,568 funds tracked by Wall St. Rank hold GILD as of Q1 2021.

  • Holowesko Partners reported no remaining Gilead Sciences position as of Q1 2021 after selling out during the quarter.
  • Holowesko Partners sold 49,000 Gilead Sciences shares in Q1 2021, an estimated $2.85M.
  • Holowesko Partners first reported a position in Gilead Sciences in Q3 2015 and held it in 19 quarters.
  • Holowesko Partners's Gilead Sciences position peaked at $98.7M in Q3 2017.
  • 1,568 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2021.

Based on Holowesko Partners's 13F filing for Q1 2021, filed 13 May 2021.